Specify a stock or a cryptocurrency in the search bar to get a summary
Cassava Sciences Inc
PX91Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Address: 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
Analytics
WallStreet Target Price
116 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures PX91
Dividend Analytics PX91
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PX91
Stock Valuation PX91
Financials PX91
Results | 2019 | Dynamics |